1. Home
  2. SHOT vs MRNS Comparison

SHOT vs MRNS Comparison

Compare SHOT & MRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SHOT
  • MRNS
  • Stock Information
  • Founded
  • SHOT 2018
  • MRNS 2003
  • Country
  • SHOT United States
  • MRNS United States
  • Employees
  • SHOT N/A
  • MRNS N/A
  • Industry
  • SHOT Biotechnology: Pharmaceutical Preparations
  • MRNS Biotechnology: Pharmaceutical Preparations
  • Sector
  • SHOT Health Care
  • MRNS Health Care
  • Exchange
  • SHOT Nasdaq
  • MRNS Nasdaq
  • Market Cap
  • SHOT 31.4M
  • MRNS 29.9M
  • IPO Year
  • SHOT 2020
  • MRNS 2014
  • Fundamental
  • Price
  • SHOT $0.53
  • MRNS $0.55
  • Analyst Decision
  • SHOT
  • MRNS Buy
  • Analyst Count
  • SHOT 0
  • MRNS 12
  • Target Price
  • SHOT N/A
  • MRNS $4.28
  • AVG Volume (30 Days)
  • SHOT 750.8K
  • MRNS 1.4M
  • Earning Date
  • SHOT 03-31-2025
  • MRNS 03-04-2025
  • Dividend Yield
  • SHOT N/A
  • MRNS N/A
  • EPS Growth
  • SHOT N/A
  • MRNS N/A
  • EPS
  • SHOT N/A
  • MRNS N/A
  • Revenue
  • SHOT $652,495.00
  • MRNS $31,466,000.00
  • Revenue This Year
  • SHOT N/A
  • MRNS $14.97
  • Revenue Next Year
  • SHOT N/A
  • MRNS $57.65
  • P/E Ratio
  • SHOT N/A
  • MRNS N/A
  • Revenue Growth
  • SHOT 68.01
  • MRNS 1.63
  • 52 Week Low
  • SHOT $0.45
  • MRNS $0.22
  • 52 Week High
  • SHOT $4.05
  • MRNS $10.50
  • Technical
  • Relative Strength Index (RSI)
  • SHOT 43.17
  • MRNS 70.09
  • Support Level
  • SHOT $0.45
  • MRNS $0.54
  • Resistance Level
  • SHOT $0.52
  • MRNS $0.55
  • Average True Range (ATR)
  • SHOT 0.05
  • MRNS 0.01
  • MACD
  • SHOT 0.01
  • MRNS -0.01
  • Stochastic Oscillator
  • SHOT 59.06
  • MRNS 93.00

About SHOT Safety Shot Inc.

Safety Shot Inc is a wellness and functional beverage company. It is set to launch Safety Shot, the patented beverage that helps people feel faster by reducing blood alcohol content and boosting clarity.

About MRNS Marinus Pharmaceuticals Inc.

Marinus Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy for the treatment of drug-resistant focal onset seizures; status epilepticus; Fragile X Syndrome, and PCDH19-RE.

Share on Social Networks: